

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022

<https://marketpublishers.com/r/PB08CEFF87AEN.html>

Date: April 2017

Pages: 280

Price: US\$ 2,400.00 (Single User License)

ID: PB08CEFF87AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022” report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. As per report findings, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.

Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being made due to which development of worthy candidates with high commercialization and pharmacological potential is expected to increase in coming years.

Investigators are trying to decipher underlying principle of cancer progression and proliferation. Different cancer indications have different requirements for developing effective therapeutics due to which identification of these factors have become important. This knowledge would be used for developing innovative cancer

immunotherapies for various malignancies.

Cancer immunotherapeutics based on these discoveries would pave path for market introduction of highly effective therapeutics. Some progress has been made which could be noticed by observing plethora of cancer immunotherapeutics available for different cancer indications. Their clinical pipeline is also developing rapidly and various products are at different stages of clinical trials. They are expected to offer severe competition to presently available cancer therapeutics with modest pharmacological efficacy.

Cancer immunotherapies have been used for limited number of malignancies as compared to other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic lymphocytic leukemia and diffuse large B cell non-Hodgkin's lymphoma have remained the focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have also got cancer immunotherapeutics.

Most like, cancer therapeutics in clinical trials would be able to present positive data that will allow them to easily enter in global market. Cancer incidences are escalating rapidly and cancer immuno therapeutics seems to play an important role in offering better medical care to patients. Some of them have received FDA's accelerated approval and breakthrough therapy designation due to their superior pharmacological benefits. It is expected that similar progress would be shown by cancer immunotherapeutics under development for different malignancies.

“Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022” report highlights:

Categorization of Cancer Immunotherapy

Market Aspects of Cancer Immunotherapy

Clinical Trials & Development Insight

Global Cancer Immunotherapy Pipeline Overview

Marketed Cancer Immunotherapy by Class

Global Cancer Immunotherapy Market Future Prospects

Competitive Analysis

Contents

1. IMMUNOTHERAPY: MENDING CANCER REGIMENS

- 1.1 Preface to Cancer Immunotherapy
- 1.2 Evolution of Cancer Immunotherapy

2. CATEGORIZATION OF CANCER IMMUNOTHERAPY

- 2.1 Specific Cancer Immunotherapy
 - 2.1.1 Cancer Vaccines
 - 2.1.2 Monoclonal Antibodies
- 2.2 Non-Specific Cancer Immunotherapy
 - 2.2.1 Adoptive Cell Transfer Immunotherapy
 - 2.2.2 Immune Checkpoint Inhibitors

3. FUNDAMENTALS OF CANCER VACCINES

- 3.1 Prologue of Cancer Vaccines
- 3.2 Cancer Vaccines in Immunotherapy
- 3.3 Commercial Aspects of Cancer Vaccines

4. NEW ERA OF MONOCLONAL ANTIBODIES

- 4.1 Rudiments of Monoclonal Antibodies
- 4.2 Advents of Monoclonal Antibodies
- 4.3 Commercial Aspects of Monoclonal Antibodies

5. TRAILS OF T-CELL THERAPIES

- 5.1 Adoptive Cell Transfer Technology
- 5.2 Strategies of Adoptive Cell Transfer
- 5.3 Commercial Aspects of Adoptive Cell Therapy

6. ASPECTS OF IMMUNE CHECKPOINT INHIBITORS

- 6.1 Prelude to Immune Checkpoint Inhibitors
- 6.2 Implications of Immunecheck Point Inhibitors
- 6.3 Commercial Aspects of Immune Checkpoint Inhibitors

7. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY

- 7.1 Perspective of Immunomodulators
- 7.2 Clinical Aspects of Immunomodulators
- 7.3 Commercial Aspects of Immunomodulators

8. ONCOLYTIC VIRAL IMMUNOTHERAPY

- 8.1 Concept to Oncolytic Viruses
- 8.2 Potential Approaches of Oncolytic Viruses
- 8.3 Commercial Aspects of Oncolytic Viruses

9. CYTOKINES IN CANCER IMMUNOTHERAPY

- 9.1 Fundamentals of Cytokines
- 9.2 Classification of Cytokines
- 9.3 Commercial Aspects of Cytokines

10. INTERFERONS IN IMMUNOTHERAPY

- 10.1 Potentials of Interferons
- 10.2 Classification of Interferons
- 10.3 Clinical Applications of Interferons

11. INTERLEUKINS IN IMMUNOTHERAPY

- 11.1 Potentials of Interleukins
- 11.2 Clinical Applications of Interleukins

12. GM-CSF IN IMMUNOTHERAPY

- 12.1 Potentials of GM-CSF
- 12.2 Clinical Applications of GM-CSF

13. GLOBAL ECONOMIC EVALUATIONS

- 13.1 Economic Aspects of Cancer Immunotherapy
- 13.2 Cancer Immunotherapy Cost by Product

14. MARKET ASPECTS OF CANCER IMMUNOTHERAPY

- 14.1 Current Market Trends
- 14.2 Cancer Immunotherapy Pipeline Overview

15. GLOBAL CANCER IMMUNOTHERAPY MARKET DYNAMICS

- 15.1 Favorable Market Parameters
- 15.2 Commercialization Challenges

16. MARKETED CANCER CELL THERAPIES DRUGS

- 16.1 Sipuleucel-T (Provenge®)
- 16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)

17. MARKETED CANCER CYTOKINES DRUGS

- 17.1 Aldesleukin (Proleukin®)
- 17.2 Denileukin Diftitox (ONTAK®)
- 17.3 Interferon Alpha (Multiferon®)
- 17.4 Interferon Alpha-2a (Roferon-A®)
- 17.5 Interferon Alpha-2a (Veldona®)
- 17.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
- 17.7 Interferon Alpha-2b(Intron® A)
- 17.8 Interferon Alpha-2b Biosimilar(Bioferon™)
- 17.9 Interferon Alpha-2b Biosimilar (Intalfa®)
- 17.10 Interferon Alpha-2b Biosimilar
- 17.11 Interferon-Alpha-n3 (Alferon N®)
- 17.12 Interferon-Beta-1b (Feron®)
- 17.13 Interferon-Gamma (Ogamma®)
- 17.14 Interleukin-2 Biosimilar (Ilcass)
- 17.15 Teceleukin (Imunace™)

18. MARKETED CANCER VACCINES

- 18.1 Bladder Cancer Vaccine (PACIS®)
- 18.2 Bladder Cancer Vaccine
- 18.3 BV NSCLC

- 18.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
- 18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
- 18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
- 18.7 Melanoma Vaccine (MVax®)
- 18.8 Melanoma Vaccine (Melacine®)
- 18.9 Racotumomab (Vaxira®)
- 18.10 Sipuleucel-T (Provenge®)
- 18.11 Tertomotide (LucaVax)
- 18.12 Vitespen (Oncophage®)

19. MARKETED CANCER MONOCLONAL ANTIBODIES

- 19.1 Bevacizumab
- 19.2 Trastuzumab Emtansine
- 19.3 Trastuzumab Subcutaneous
- 19.4 Brentuximab Vedotin
- 19.5 Catumaxomab
- 19.6 Ipilimumab
- 19.7 Nivolumab
- 19.8 Pembrolizumab
- 19.9 Pertuzumab
- 19.10 Rituximab
- 19.11 Trastuzumab

20. GLOBAL CANCER IMMUNOTHERAPY MARKET FUTURE PROSPECTS

21. COMPETITIVE LANDSCAPE

- 21.1 Abbvie
- 21.2 Advaxis
- 21.3 Altor BioScience
- 21.4 Amgen
- 21.5 Biogen Idec
- 21.6 Biogenomics
- 21.7 Celldex Therapeutics
- 21.8 Dendreon Corporation
- 21.9 Eli Lilly
- 21.10 Expression Genetics
- 21.11 Galena Biopharma

- 21.12 Genmab
- 21.13 Gilead Sciences
- 21.14 GlaxoSmithKline
- 21.15 ImmunoCellular Therapeutics
- 21.16 ImmunoGen
- 21.17 Inovio Pharmaceuticals
- 21.18 IRX Therapeutics
- 21.19 Merck
- 21.20 NeoStem Oncology
- 21.21 NewLink Genetics
- 21.22 Northwest Biotherapeutics
- 21.23 Novartis
- 21.24 Peregrine Pharmaceuticals
- 21.25 Pfizer
- 21.26 Philogen
- 21.27 Regulon
- 21.28 Roche
- 21.29 Seattle Genetics
- 21.30 ZymoGenetics

List Of Figures

LIST OF FIGURES

- Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
- Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
- Figure 1-3: Potential Benefits of Cancer Immunotherapies
- Figure 2-1: Classification of Cancer Immunotherapies
- Figure 2-2: Categorization of Specific Immunotherapy
- Figure 2-3: Non-Specific Cancer Immunotherapies
- Figure 3-1: Categorization & Function of Cancer Vaccines
- Figure 3-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
- Figure 3-3: Global Cancer Vaccines Market (US\$ Billion), 2016-2022
- Figure 4-1: Process of Manufacturing of Monoclonal Antibody
- Figure 4-2: Principles of Monoclonal Antibodies
- Figure 4-3: Evolution of Monoclonal Antibody over Generations
- Figure 4-4: Classification of Monoclonal Antibodies
- Figure 4-5: Representation of Mechanism of Alemtuzumab
- Figure 4-6: Representation of Mechanism of Ibritumomab Tiuxetan
- Figure 4-7: Representation of Mechanism of Blinatumomab
- Figure 4-8: Global Market for Cancer Monoclonal Antibodies (US\$ Billion), 2016-2022
- Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
- Figure 5-2: Systematic Representation of Adoptive T-Cell Therapies
- Figure 5-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
- Figure 5-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
- Figure 5-5: Mechanism of CAR Modified T-Cells
- Figure 5-6: Genetically Engineered TCR for Cancer Immunotherapy
- Figure 5-7: Global Predictive Market of CAR T-Cell Therapeutics (US\$ Million), 2016-2022
- Figure 6-1: Benefits of Immune Checkpoint Inhibitors
- Figure 6-2: Implication of Adaptive Immune Resistance Mechanism
- Figure 6-3: Mechanism of Ipilimumab
- Figure 6-4: Layout of Mechanism of Nivolumab
- Figure 6-5: Mechanism of Pembrolizumab
- Figure 6-6: Global - Immune Check Point Inhibitors Market (US\$ Billion), 2016-2022
- Figure 7-1: Functions of Immunomodulators
- Figure 7-2: Benefits of Immunomodulators
- Figure 7-3: Layout of the Challenges of Immunomodulators
- Figure 7-4: Properties of Thalidomide

Figure 7-5: Mechanism of Lenalidomide In Vivo

Figure 7-6: Mechanism of Lenalidomide in Vitro

Figure 7-7: Mechanism of Pomalidomide

Figure 7-8: The Global Market for Immunomodulators for All Indications (US\$ Billion), 2016-2022

Figure 8-1: Demonstration of Categorization of Oncolytic Viruses

Figure 8-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies

Figure 8-3: The Predicted Market Share of Oncolytic Viral Therapies (US\$ Million), 2016-2022

Figure 9-1: Layout of Functions Performed by Cytokine

Figure 9-2: Benefits of Cytokines in Cancer Immunotherapy

Figure 9-3: Classification of Cytokine Receptor Family

Figure 9-4: Percentage Share of the Cancer Immunotherapies by the Technology

Figure 10-1: Layout of Functions of Interferon

Figure 10-2: Classification of Interferons on the Basis of Types of Genes

Figure 10-3: General Mechanism of Interferons

Figure 10-4: Mechanism of Interferon Alfa-n3

Figure 10-5: Aspects of Peginterferon Alfa-2a

Figure 10-6: Applications of Interferon Beta 1a

Figure 10-7: Potentials of Interferon Alfa-2b

Figure 11-1: Functions of Interleukin

Figure 11-2: Potentials of Interleukins in Cancer Immunotherapy

Figure 11-3: Clinical Potentials of Proleukin

Figure 11-4: Clinical Potentials of Denileukin Diftitox

Figure 12-1: Potential Applications of GM-CSF

Figure 12-2: Mechanism of Sargramostim

Figure 13-1: Expected Cancer Treatment Cost (US\$ Billion), 2016-2022

Figure 13-2: Comparative Analysis of Available Cancer Treatments

Figure 13-3: Major Approved Immunotherapeutic Drugs

Figure 13-4: Annual per Patient Drug Expenditure of Immunotherapy

Figure 14-1: Global Cancer Immunotherapeutic Market (US\$ Billion), 2016-2022

Figure 14-2: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2017 - 2022

Figure 14-3: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-4: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-5: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-6: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-7: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-8: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-9: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-10: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-11: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 - 2022

Figure 14-12: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2017 - 2022

Figure 14-13: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2017 - 2022

Figure 15-1: Favorable Cancer Immunotherapy Market Parameters

Figure 15-2: Cancer Immunotherapy Commercialization Challenges

Figure 21-1: Advaxis Clinical Pipeline

Figure 21-2: Celldex Therapeutics Clinical Pipeline

Figure 21-3: Expression Genetics Clinical Pipeline

Figure 21-4: Galena Biopharma Clinical Pipeline

Figure 21-5: ImmunoCellular Therapeutics Clinical Pipeline

Figure 21-6: ImmunoGen Clinical Pipeline

Figure 21-7: Inovio Pharmaceuticals Clinical Pipeline

Figure 21-8: NewLink Genetics Corporation Clinical Pipeline

Figure 21-9: Northwest Biotherapeutics Clinical Pipeline

Figure 21-10: Peregrine Pharmaceuticals Clinical Pipeline

Figure 21-11: Philogen Clinical Pipeline

Figure 21-12: Seattle Genetics Clinical Pipeline

List Of Tables

LIST OF TABLES

Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy

Table 6-1: Illustration of Some Important Checkpoint Inhibitors

Table 9-1: Few Important Immunocytokines under Clinical Development

Table 9-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies

Table 14-1: Few Commercially Important PD-1 Drugs

I would like to order

Product name: Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022

Product link: <https://marketpublishers.com/r/PB08CEFF87AEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB08CEFF87AEN.html>